Article in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Satyesh K SinhaDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-8735-6303
Chantle R SwichkowDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.
Lia FarahiDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.
Miklós PéterfyDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-5280-0216
Calvin PanDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-0752-833X
Zhiqiang ZhouDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-8914-0864
Marcus M SeldinDepartment of Biological Chemistry and Center for Epigenetics and Metabolism, University of California, Irvine (M.M.S.).ORCID 0000-0001-8026-4759
Julia J MackDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-9239-8436
Richard C DavisDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.
Diana M ShihDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0002-2848-3492
Aldons J LusisDepartment of Medicine/Division of Cardiology (S.K.S., C.R.S., L.F., M.P., C.P., Z.Z., J.J.M., R.C.D., D.M.S., A.J.L.), University of California Los Angeles.ORCID 0000-0001-9013-0228
Funding
Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVIS, RICHARD C · 1985 to 2019
$50.2M
Vascular Biology Training GrantT32HL069766 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2002 to 2022
$7.4M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
Systems genetics approach to inflammatory mechanisms in atherosclerosisR01HL147883 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2019 to 2022
$3.0M
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitisR44DK136405 · NIDDK · MAX BIOPHARMA, INC. · PI PARHAMI, FARHAD · 2023 to 2024
backgroundIn genetic studies with the Hybrid Mouse Diversity Panel, we previously identified a chromosome 9 locus for atherosclerosis. We now identify NNMT (nicotinamide
methodsGain/loss of function studies in macrophages were performed to examine the role of NAD levels in macrophage proliferation and apoptosis in atherosclerosis.
resultsGlobal inhibition of NNMT using an antisense oligonucleotide reduced atherosclerosis lesion area 5- to 10-fold in both male and female mice on a hyperlipidemic background. Selective inhibition of NNMT in liver and adipose, the major tissues expressing high levels of the enzyme, using siRNA (small interfering RNA), had little or no effect on atherosclerosis. Therefore, we hypothesized that levels of NAD in macrophages might contribute. This was confirmed by showing that transplantation with bone marrow from
conclusionsThese findings reveal a role for nicotinamide salvage and NAD turnover in macrophage proliferation and survival in the context of atherosclerosis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
NAD Metabolism Regulates Proliferation of Macrophages in Atherosclerosis. · full record | Socratic